Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer

Pretreatment AMH is a useful predictor of long term post chemotherapy loss of ovarian function in women with eBC, adding significantly to the only previously established individualising predictor, i.e. age. AMH measurement may assist decision-making regarding treatment options and fertility preservation procedures.